233 related articles for article (PubMed ID: 15757201)
1. Analysis of P161NK4A protein expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201
[TBL] [Abstract][Full Text] [Related]
2. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):133-41. PubMed ID: 15757200
[TBL] [Abstract][Full Text] [Related]
3. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Satacińska-Los E; Kulig A; Włoch J
Pol J Pathol; 2005; 56(1):27-35. PubMed ID: 15921011
[TBL] [Abstract][Full Text] [Related]
4. Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Włoch J; Sałacińska-Los E; Kulig A; Jarzab B
Pol J Pathol; 2004; 55(4):149-53. PubMed ID: 15757202
[TBL] [Abstract][Full Text] [Related]
5. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
9. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
West J; Munoz-Antonia T; Johnson JG; Klotch D; Muro-Cacho CA
Laryngoscope; 2000 Aug; 110(8):1323-7. PubMed ID: 10942134
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions.
Lewy-Trenda I; Bieńkiewicz M
Pol J Pathol; 1999; 50(3):129-38. PubMed ID: 10624114
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
14. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
18. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer.
Wang S; Lloyd RV; Hutzler MJ; Safran MS; Patwardhan NA; Khan A
Mod Pathol; 2000 Aug; 13(8):882-7. PubMed ID: 10955455
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
20. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]